Cristian Massacesi MD

Cristian Joined Novartis in Sep 2006 as Medical Director (Oncology European Medical Affairs), responsible for solid tumors franchise activities. In 2008, Sr Global Clinical Leader, NJ (US), led the clinical development of Afinitor (Everolimus) in breast cancer (Bolero program). In 2010, Paris (France) site Head for Oncology Global Development and Medical Affairs team (about 100 associates) and as Vice-President, Sr. Global Clinical Program Head (GCPH) led the clinical program for PI3K inhibitors portfolio. In 2016, clinical accountability for Zykadia(Ceritinib) program and the 3 concomitant submissions followed by approvals in ALK-positive NSCLC. Sr. GCPH Center of Excellence of Immunotherapy for Immuno-Oncology assets in full development.

In 2017 joined Pfizer Global Product Development Oncology as Vice President, Medicine Team Leader Immuno-Oncology, NY (US), leading the development programs of Utomilumab (4-1BB agonist mAb), PF-06747775 (EGFR-T790M Inhibitor) and Avelumab (PD-L1 mAb) programs in Head & Neck, Hematology malignancies, and some of the innovative combinations. Active role in the External Partnering Committee, Oncology Business Development and Pipeline Strategy. Produced on a wide range of cancer topics, with 47 extended peer-reviewed publications and more than 100 meeting communications.